4-硝基苯氧基乙酸肼 | 75129-74-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-硝基苯氧基乙酸肼
• 英文名称: (4-nitro-phenoxy)-acetic acid hydrazide
• 英文别名: 2-(4-nitrophenoxy)acetohydrazide；p-nitrophenoxy acetyl hydrazide；4-Nitrophenoxyacetic acid hydrazide
• CAS: 75129-74-7
• 化学式: C₈H₉N₃O₄
• mdl: MFCD00051973
• 分子量: 211.177
• InChiKey: BDPKZWIKLVUGKS-UHFFFAOYSA-N

物化性质

• 熔点：
  184-186°C
• 稳定性/保质期：
  远离氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2928000090
• 储存条件：
  存放在密封容器中，并放置在阴凉、干燥处。请确保储存地点远离氧化剂。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Nitrophenoxyacetic acid hydrazide
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Nitrophenoxyacetic acid hydrazide
Ingredient name:
CAS number: 75129-74-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H9N3O4
Molecular weight: 211.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-硝基苯氧基乙酸肼 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 N-[[5-methyl-2-oxo-1-(piperidin-1-ylmethyl)indol-3-ylidene]amino]-2-(4-nitrophenoxy)acetamide
  参考文献：
  名称：

  N,N-二取代的1-(氨基甲基)-5-烷基-3-(芳氧基乙酰基腙)吲哚-2-酮的合成和CNS活性

  摘要：

  靛红和 5-甲基靛红与各种芳氧基乙酰肼缩合得到 3-（芳氧基乙酰肼）-5- 烷基吲哚 - 2 - 1-4。当1-4进行曼尼希反应时，得到N，N-双取代的1-（氨甲基）-5-烷基-3-（芳氧基乙酰基腙）吲哚-2-5-8。这些化合物具有 CNS 活性并且相对无毒（白化小鼠）。

  DOI：

  10.1002/ardp.19823150207
• 作为产物：
  描述：

  4-硝基苯氧乙酸 在 一水合肼 、 乙酰氯 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 4-硝基苯氧基乙酸肼
  参考文献：
  名称：

  新型8-羟基喹啉衍生物及其Eu（III）配合物的合成与发光性能

  摘要：

  以2-甲基-8-羟基喹啉和对位取代苯酚为主要原料合成了六种新颖的8-羟基喹啉衍生物，并通过1 H核磁共振（NMR），质谱（MS），紫外（UV）进行了表征光线分析和红外（IR）光线分析。还制备了它们与Eu（III）的配合物，并通过元素分析，摩尔电导率，UV光分析，IR光分析和热重-差热分析（​​TG-DTA）对其进行了表征。结果表明，该配体与Eu（III）离子配位良好，并具有优异的热稳定性。靶复合物的结构是EuY 1-6（NO 3）3 ·2H 2O.研究了目标配合物的发光性能，结果表明所有目标配合物均具有良好的发光性能，并且给电子基团的引入可增强相应配合物的发光强度，但添加电子退出组的效果相反。在所有目标络合物中，甲氧基取代的络合物（–OCH 3）的荧光强度最高，而硝基取代的络合物（–NO 2）的荧光强度最弱。结果表明，8-羟基喹啉衍生物对Eu（III）离子具有良好的能量转移效率。所有目标复

  DOI：

  10.1002/bio.3482

文献信息

• [EN] AGENT FOR PREVENTING OR TREATING NEUROPATHY<br/>[FR] AGENT POUR LA PRÉVENTION OU LE TRAITEMENT DE NEUROPATHIE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2004039365A1

  公开（公告）日：2004-05-13

  The present invention provides an agent for preventing or treating neuropathy having superior action and low toxicity. This agent comprises a compound represented by the formula:wherein ring A is a 5-membered aromatic heterocycle containing 2 or more nitrogen atoms, which may further have substituent(s);B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;X is a divalent acyclic hydrocarbon group;Z is -O-, -S-, -NR2-, -CONR2- or -NR2CO- (R2 is a hydrogen atom or an optionally substituted alkyl group);Y is a bond or a divalent acyclic hydrocarbon group;R1 is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, provided that when the 5-membered aromatic heterocycle represented by ring A is imidazole, then Z should not be -O-, or a salt thereof.

  本发明提供了一种具有优越作用和低毒性的预防或治疗神经病的药剂。该药剂包括一个由以下式表示的化合物：其中环A是含有2个或更多氮原子的5元芳香杂环，可能进一步具有取代基；B是一个可选择取代的碳氢基团或可选择取代的杂环基团；X是二价的无环碳氢基团；Z是-O-，-S-，-NR2-，-CONR2-或-NR2CO-（R2是氢原子或可选择取代的烷基基团）；Y是键或二价的无环碳氢基团；R1是可选择取代的环基团，可选择取代的氨基团或可选择取代的酰基团，但当环A表示的5元芳香杂环是咪唑时，Z不应为-O-，或其盐。
• Synthesis and in-vitro antimicrobial activity of new 1,2,4-triazoles
  作者：A R Bhat、G Varadaraj Bhat、G Gautham Shenoy

  DOI：10.1211/0022357011775307

  日期：2010.2.18

  described the synthesis of new 1,2,4-triazoles and have evaluated their antimicrobial profile. Antitubercular activity was determined in triplicate using the Lowenstein-Jensen medium. A loopful of Mycobacterium tuberculosis suspension was inoculated on the surface of each Lowenstein-Jensen media containing the test compounds (100, 10 or 1 microg mL(-1)). To evaluate in-vitro antibacterial activity, compounds

  我们已经描述了新的1,2,4-三唑的合成，并评估了它们的抗菌特性。使用Lowenstein-Jensen培养基一式三份确定抗结核活性。在含有测试化合物（100、10或1微克mL（-1））的每种Lowenstein-Jensen培养基的表面上接种一圈结核分枝杆菌悬液。为了评估体外抗菌活性，通过圆盘扩散法对枯草芽孢杆菌，大肠杆菌，铜绿假单胞菌，金黄色葡萄球菌和伤寒葡萄球菌评估了化合物（50、5或0.5微克）。为了评估抗真菌活性，使用了Sabourauds葡萄糖琼脂培养基。筛选了某些化合物（5、0.5或0.05微克mL（-1））的抗黑曲霉88和黑曲霉90的活性，而其他化合物则抗T的活性。使用杯板法将红花TR1，红花R.R6，红花R7和薄荷茶T. 我们的结果表明，与在分子4位具有吡嗪部分的三唑相比，在3位具有吡嗪部分的三唑作为抗结核剂和抗真菌剂更具活性。
• [EN] SELECTIVE NR2B ANTAGONISTS<br/>[FR] ANTAGONISTES SÉLECTIFS DU NR2B
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013049119A1

  公开（公告）日：2013-04-04

  The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及到式(I)的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是配体，NR2B受体的拮抗剂，可能对治疗中枢神经系统的各种疾病有用。
• Synthesis and xanthine oxidase inhibitory activity of 7-methyl-2-(phenoxymethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one derivatives
  作者：K.R. Sathisha、Shaukath A. Khanum、J.N. Narendra Sharath Chandra、F. Ayisha、S. Balaji、Gopal K. Marathe、Shubha Gopal、K.S. Rangappa

  DOI：10.1016/j.bmc.2010.11.034

  日期：2011.1

  gastrointestinal upset, skin rashes and hypersensitivity reactions. Moreover, an elevated level of uric acid is considered as an independent risk factor for cardiovascular diseases. Therefore use of allopurinol-like drugs with minimum side effects is the ideal drug of choice against gout. In this study, we report the synthesis of a series of pyrimidin-5-one analogues as effective and a new class of xanthine oxidase

  血尿酸水平升高（高尿酸血症）是痛风的根本原因。黄嘌呤氧化酶是催化次黄嘌呤氧化为黄嘌呤然后变为尿酸的关键酶。别嘌醇是一种广泛使用的黄嘌呤氧化酶抑制剂，是治疗痛风的最常用药物。但是，一小部分人却遭受别嘌醇的不良影响，包括胃肠道不适，皮疹和超敏反应。此外，尿酸水平升高被认为是心血管疾病的独立危险因素。因此，使用副作用最小的类别嘌呤醇类药物是对抗痛风的理想药物选择。在这项研究中，我们报告了一系列有效的嘧啶5一类似物和一类新的黄嘌呤氧化酶抑制剂的合成。所有合成的嘧啶-5-酮类似物均通过光谱技术和元素分析进行​​表征。四（在该类别的20个合成分子中，图6a，6b，6d和6f）显示出对三种不同的黄嘌呤氧化酶的良好抑制作用，基于它们各自的IC 50值，它们比别嘌呤醇更有效。分子建模和对接研究表明，分子6a与黄嘌呤氧化酶的关键成分钼－氧－硫（MOS）复合物具有很好的相互作用。这些结果突出了鉴定出一种新型的黄
• 2,5-取代基-1,3,4-噁（噻）二唑硫醚类衍生物、其制备方法及应用
  申请人：贵州大学

  公开号：CN106432125A

  公开（公告）日：2017-02-22

  本发明公开了一种2,5‑取代基‑1,3,4‑噁（噻）二唑硫醚类衍生物、其制备方法及应用，其通式如下：(I)其中：R1为4‑氯苯基、4‑氟苯基、4‑甲基苯基、4‑甲氧基苯基、4‑硝基苯基、4‑氰基‑3,5‑二氟苯基、4‑三氟甲基苯基、4‑三氟甲氧基苯基、4‑叔丁基苯基、2‑氟苯基等取代基；R2为甲基、乙基、4‑氯苄基、2,4‑二氯苄基、4‑三氟甲氧基、苄基、4‑氟苄基、4‑氯苄基等取代基；X为O或S。本发明的化合物可用作杀农作物线虫和抑制作物细菌性病的药物。